Therapeutic Areas: Parkinson’s disease and Erectile Dysfunction
Phase of Development: IND in preparation
IND in preparation
FKP has a goal to develop an apomorphine pro drug with prolonged therapeutic antiparkinson effects suitable for delivery orally (once a day), transdermally (once a week) and as an implant (once every six months). Also, the drug should produce near complete relief of Parkinson symptoms without dyskinesias. To this end, FKP has the patent rights to a large series of apomorphine monoesters and mixed esters.
The lead compound, FKK01PD, is an orally active postsynaptic D1 and D2 agonist. The drug has a similar action to apomorphine without the toxicity and short duration of activity of apomorphine.
In freely moving rats with an indwelling interstitial cannula, FKK01PD, given orally in enteric coated capsules showed obvious behavioral signs of dopamine stimulation for at least 10 hours. Dopamine and DOPAC measured by HPLC from the cannula showed significant decreases indicating dopamine receptor agonism.
Three studies have been conducted on MPTP lesioned levodopa treated marmoset’s at Dr. Tom Chase’s lab at the NIH. FKK01PD given orally in an enteric coated capsule produced optimal antiparkinson activity for 33 hours. Multiple dosing for 7 days produced excellent results with a 28 hour “on” after the last dose. A pharmacokinetic study in these animals demonstrated blood levels out to 36 hours.
These results indicate that this is an important compound which could be moved along quickly. The manufacturing, pharmacology and toxicology are ready for IND preparation.
Protocols in development.
Developmental and licensing opportunities are available.